Emerik Osterlund

MD PhD
Advanced Postdoctoral Research Fellow at MD Anderson Cancer Center
Resident Physician in Clinical Oncology at University of Turku

[Vumedi Oncology @VuMediHemOnc]

🧬 What should clinicians do when ctDNA becomes positive after curative-intent treatment for CRC?

Dr. Emerik Osterlund @EmerikOsterlund of @UTMDAnderson reviews INTERCEPT data on stage-specific ctDNA positivity rates, MRD detection, and how molecular findings are shaping real-world clinical management.

🎥 Watch on #Vumedi: https://t.co/EgWXYNFwkI

#ctDNA #MRD

[UT MD Anderson @UTMDAnderson]

Data from the prospective INTERCEPT program presented by Dr. Emerik Osterlund at #ASCO26 reinforce the prognostic value of ctDNA and show how MRD detection is influencing surveillance, diagnostic workups, treatment decisions, and clinical trial enrollment across stages of colorectal cancer. @EmerikOsterlund @skopetz #EndCancer 4/12

[Van Morris, MD @VanMorrisMD]

What @UTMDAnderson clinical trial options are available for ctDNA(+) CRC MRD?

Yesterday our incredible panel of speakers at inaugural CRC INTERCEPT symposium answered this & brought all the updates for use of ctDNA for CRC mgmt!

Check out https://t.co/rrjVteRl2x for details!

[Vumedi Oncology @VuMediHemOnc]

Dr. @EmerikOsterlund presents real-world findings from the INTERCEPT study:
Only ~4% of CRC patients show spontaneous ctDNA clearance—a key baseline when using MRD clearance as a trial endpoint. @ecancer @MDAndersonNews

Watch on Vumedi: https://t.co/ppBArJqyC1
#CRC #ESMO2025

[OncLive.com @OncLive]

ctDNA Clearance With Adjuvant Therapy Is Associated With Improved DFS in CRC @EmerikOsterlund @MDAndersonNews @myESMO #ESMO25 https://t.co/8TzrD3n7eU

[Van Morris, MD @VanMorrisMD]

Excellent talk from @EmerikOsterlund presenting research on ctDNA clearance patterns from pts w/ CRC in @MDAndersonNews INTERCEPT. Historical precedent for spontaneous ctDNA clearance using WES approach will help inform future trial design! Accompanied by insightful perspective from the always incredible @aparna1024 . #endcancer

[Paolo Ciracì @p_ciracimd]

@VanMorrisMD @EmerikOsterlund @MDAndersonNews Excellent presentation @EmerikOsterlund 👏

[Emerik Osterlund @EmerikOsterlund]

@GIMedOnc @TumorBoardTues @aparna1024 @IntegrityCE Clinical trials would certainly be an option. However, many of them require prior standard-of-care adjuvant therapy for eligibility.

[#TumorBoardTuesday @TumorBoardTues]

@EmerikOsterlund @aparna1024 @IntegrityCE @MPishvaian #TumorBoardTuesday

👏This was a #MASTERCLASS on ctDNA testing for #colorectalcancer led by @aparna1024 and @EmerikOsterlund

Thank you so much for taking a TON of data, and making it so understandable and applicable for the benefit of our patients 🙏🙏🙏

[Emerik Osterlund @EmerikOsterlund]

@TumorBoardTues @aparna1024 @IntegrityCE @MPishvaian #TumorBoardTuesday

@TumorBoardTues
Thank you very much for the opportunity to host this session, I had a blast!😃

[Emerik Osterlund @EmerikOsterlund]

@TumorBoardTues @aparna1024 @IntegrityCE 23/23 #TumorBoardTuesday
🔑Takeaways 2/2
✅Stage 2 CRC: ctDNA⛔️; ❓consider chemo de-escalation/avoidance
🔁Serial testing matters; On-treatment ctDNA “clearance” can be transient
🧪Pair ctDNA with clinical assessment and 🩻; assay & timing matters

[Emerik Osterlund @EmerikOsterlund]

@TumorBoardTues @aparna1024 @IntegrityCE 22/23 #TumorBoardTuesday
🔑Takeaways 1/2
🧬ctDNA useful for MRDdetection after surgery
⚠️ ctDNA➕→ very high recurrence risk; ❓consider adjuvant/intensified chemo

[Emerik Osterlund @EmerikOsterlund]

@TumorBoardTues @aparna1024 @IntegrityCE @MPishvaian #TumorBoardTuesday

@TumorBoardTues
Thank you very much for the opportunity to host this session, I had a blast!😃

[Emerik Osterlund @EmerikOsterlund]

@HannahAlison20 @TumorBoardTues @aparna1024 @IntegrityCE @MPishvaian I am glad to hear that, thank you very much for participating and contributing!

[Emerik Osterlund @EmerikOsterlund]

@MPishvaian @TumorBoardTues @aparna1024 @IntegrityCE Really challenging indeed, to say the least 🤔

[Emerik Osterlund @EmerikOsterlund]

@TumorBoardTues @aparna1024 @IntegrityCE #TumorBoardTuesday
@TumorBoardTues Thank you very much for the opportunity to present!
@aparna1024 for great co-operation of preparing the and conducting the session!
@MPishvaian for your great comments and questions!

[Emerik Osterlund @EmerikOsterlund]

@TumorBoardTues @aparna1024 @IntegrityCE 23/23 #TumorBoardTuesday
🔑Takeaways 2/2
✅Stage 2 CRC: ctDNA⛔️; ❓consider chemo de-escalation/avoidance
🔁Serial testing matters; On-treatment ctDNA “clearance” can be transient
🧪Pair ctDNA with clinical assessment and 🩻; assay & timing matters

[Emerik Osterlund @EmerikOsterlund]

@yeung_cynthia @TumorBoardTues @aparna1024 @IntegrityCE Thank you very much!

I am a firm believer in tumor informed assays in the MRD setting, as long as we have tumor material for designing them.

[Emerik Osterlund @EmerikOsterlund]

@TumorBoardTues @aparna1024 @IntegrityCE #PostTest Q2️⃣ #TumorBoardTuesday
👉🏽 Free CME 🔗 https://t.co/2Jdml74CPZ

🧐70M, frail + comorbidities, s/p upfront surgery for sigmoid mass. Final pathology: pT3N0 (stage IIA). 2 months post-op: ctDNA-negative. What’s next?

[Emerik Osterlund @EmerikOsterlund]

@TumorBoardTues @aparna1024 @IntegrityCE #PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval 🔗 https://t.co/pWxDXtEGHz
👉🏽ALL CME🔗 https://t.co/2Jdml74CPZ

🧐ctDNA monitoring after CRC resection: